Metabolic Solutions Development Company Announces Publication of Phase 2b Data in Clinical Pharmacology & Therapeutics

KALAMAZOO, Mich., Jan. 24, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company’s prototype insulin sensitizer in patients diagnosed with type 2 diabetes. The data demonstrate MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators™, met the study’s primary endpoint of significantly reducing fasting plasma glucose (FPG) and significantly reduced hemoglobin A1c (HbA1c).

PDF:
Metabolic Solutions Development Company Announces Publication of Phase 2b Data in Clinical Pharmacology & Therapeutics 1-24-2013